Egetis Therapeutics & Anovo Unite for MCT8 Patients
January 2, 2024
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
What is MCT8 Deficiency (Allan-Herndon-Dudley Syndrome)?
MCT8 deficiency, a rare and debilitating disorder also known as Allan-Herndon-Dudley Syndrome, poses significant challenges for affected individuals and their loved ones. This genetic condition primarily affects brain development and function, leading to developmental delays, muscle weakness, and neurological impairments. Despite its rarity, the impact of Allan-Herndon-Dudley Syndrome is profound, underscoring the urgent need for effective treatments and interventions to improve the quality of life for those affected.
Egetis Therapeutics Partners with Anovo
At Anovo, we’re proud to work with Egetis Therapeutics to help more patients access their innovative new therapy for MCT8 deficiency. Since there is currently no available approved treatment for MCT8 deficiency, our partnership enables us to administer the Egetis Early Access Program (EAP), providing hope and support to patients and families facing the challenges of MCT8 deficiency. Together, we’re committed to advancing the field of rare disease treatment, working towards a brighter future for our patients and their caregivers.
Related Posts
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 30, 2025
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
